Preimplantation Genetic Testing Market Size, Industry Analysis and Forecast 2032

0
28

According to a new report published by K D Market Insights, titled, “Preimplantation Genetic Testing Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global preimplantation genetic testing market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The increasing demand for advanced genetic testing technologies in assisted reproductive procedures. PGT enables the detection of genetic abnormalities in embryos before implantation, ensuring healthier pregnancies and reducing the risk of genetic disorders which are the major factors augmenting the growth of the global preimplantation genetic testing market.

PGT enables the examination of embryos beyond their superficial appearance, substantially reducing the chances of conceiving unhealthy embryos which is further expected to create ample growth opportunities for the global preimplantation genetic testing market during the forecast period i.e., 2023-2032. Moreover, development of savior siblings and an increased adoption of assisted reproductive technology (ART) in developing countries. The option to create savior siblings through PGT, providing potential treatments for genetic conditions in existing siblings has propelled market expansion. Growing risk of fatal genetic, hereditary, and chromosomal diseases, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global preimplantation genetic testing market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the increasing healthcare spending and a growing population seeking assisted reproductive technology (ART) solutions.

According to technology, the next generation sequencing segment accounted for the largest market share in the preimplantation genetic testing market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global preimplantation genetic testing market is segmented into technology, product & service, procedure type, application, end user and region. Based on technology, the market is bifurcated into next generation sequencing (NGS), polymerase chain reaction (PCR), fluorescent in-situ hybridization (FISH), comparative genomic hybridization (CGH), single nucleotide polymorphism (SNP), others. Based on, product & service, it is classified into reagents & consumables, instruments, software & services. Based on procedure type, it is classified into preimplantation genetic screening, preimplantation genetic diagnosis. Based on application, it is classified into aneuploidy, structural chromosomal abnormalities, single gene disorders, X-linked disorders, HLA typing, others. Based on end user, it is classified into maternity centers & fertility clinics, hospitals, diagnostic labs, and service providers, research laboratories & academic institutes

Related Reports :-

https://www.kdmarketinsights.com/reports/endoscope-drying-cabinets-market/7334

https://www.kdmarketinsights.com/reports/regenerative-medicine-market/7333

https://www.kdmarketinsights.com/reports/transseptal-access-systems-market/7332

https://www.kdmarketinsights.com/reports/saliva-based-testing-screening-market/7331

The global preimplantation genetic testing market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Preimplantation Genetic Testing Market

  • On the basis of technology, the next generation sequencing segment accounted for the largest market share in the preimplantation genetic testing market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
  • On the basis of region, North America accounted for the largest share in the global preimplantation genetic testing market in 2022. The region is further projected to continue dominating in the market during the forecast period.
  • On the basis of region, Europe is estimated to account for the second largest share in the market during the forecast period.

Some of the major preimplantation genetic testing companies profiled in the report include Oxford Gene Technology, Thermo Fisher Scientific Inc., SciGene Corporation, Agilent Technologies Inc., PerkinElmer Inc., Coopersurgical Inc., Abbott Laboratories, Illumina Inc., Natera Inc., Yikon Genomics, Beijing Genomics Institute (BGI), Genea Limited, Rubicon Genomics, Inc., and Oxford Gene Technology.